(2S)-2-azido-3-(tert-butoxy)propanoic acid; cyclohexanamine

Compound number
MolPort-021-795-100
CAS number
1228077-87-9
IUPAC
(2S)-2-azido-3-(tert-butoxy)propanoic acid; cyclohexanamine
IUPAC traditional
(2S)-2-azido-3-(tert-butoxy)propanoic acid; cyclohexylamine
SMILES
NC1CCCCC1.CC(C)(C)OC[C@H](N=[N+]=[N-])C(O)=O |r|
InChI key
KUVVCFAAYOBPAV-JEDNCBNOSA-N
Molecular formula
Molecular weight
286.376
Solubility
not available

Marketplace Offers

Chiralix

Direct S&H to USA 100.00 USD Direct S&H to World: 110.00 USD
Catalog
Building blocks
Ships out
3 business days
Purity
>95%
Last updated
3 months ago
In warehouse
8.10 g

Supplier Catalogue Data

Pack size Ships out Price Quantity
1 g May 25, 2022 198.00 USD
Add to Cart Buy
5 g May 25, 2022 666.00 USD
Add to Cart Buy

Apollo Scientific

Direct S&H to USA 45.00 USD Direct S&H to World: 80.00 USD
Catalog
Building blocks
Ships out
5 business days
Purity
n/a
Last updated
> 3 months ago
In warehouse
Unverified

Supplier Catalogue Data

Pack size Ships out Price Quantity
1 g May 27, 2022 436.00 USD
Add to Cart Buy

More Information

Compound identifiers

Compound number
MolPort-021-795-100
CAS number
1228077-87-9

Names, Synonyms and 3rd Party Identifiers

Name
L-azidoserine tert-butyl ether CHA salt
Propanoic acid, 2-azido-3-(1,1-dimethylethoxy)-, compd. with cyclohexanamine (1:1), (2S)-
cyclohexanaminium (S)-2-azido-3-tert-butoxypropanoate
MFCD11223827

InChI

InChI
1/C7H13N3O3.C6H13N/c1-7(2,3)13-4-5(6(11)12)9-10-8;7-6-4-2-1-3-5-6/h5H,4H2,1-3H3,(H,11,12);6H,1-5,7H2/t5-;/m0./s1
InChI key
KUVVCFAAYOBPAV-JEDNCBNOSA-N

Formula

Molecular formula
C13H26N4O3
Molecular weight
286.376

MolPort Guarantee

When you purchase products through the MolPort website from any seller other than MolPort itself, you will be protected by the MolPort Guarantee. If you purchase products from MolPort itself, this MolPort Guarantee will not apply, and your remedies will be governed by the MolPort Terms of Sale and Supply.

Copyright 2022 MolPort. All rights reserved. v5.96

We use cookies to improve your experience on our websites and for advertising. Learn more Accept

Feedback